Literature DB >> 26221904

Comparison of snakebite cases in children and adults.

R Tekin1, B Sula, G Cakırca, F Aktar, Ö Deveci, I Yolbas, M K Çelen, M Bekcibasi, Y Palancı, E Dogan.   

Abstract

OBJECTIVE: There are very few studies that compare the snakebite cases in children and adults. The present study aimed to compare the demographic characteristics, clinical presentations, laboratory findings, and developed complications in pediatric and adult patients due to snakebites. PATIENTS AND METHODS: This study included the patients admitted to the hospital and monitored due to snakebite between July 1999 and December 2012. The condition of each patient who had been bitten was admitted to the hospital was monitored from the time of admission to the end of their hospital stay. The fact that a snakebite occurred was recorded if the subjects saw the snake or if the appearance of the puncture sites was convincingly a snakebite.
RESULTS: The present work included 290 patients, of whom 123 were children and 167 were adults. The most common location of the bites was the lower extremity with 78.9% (n=97) and 63.5% (n=106) in pediatric and adult patients, respectively. All of the pediatric patients received prophylactic treatment with antibiotics, whereas 62 (37.1%) adult patients received antimicrobial treatments due to the soft tissue infection. The most common complication developed was pulmonary edema in children at a rate of 33.3% (n=41) and compartment syndrome in adult patients at a rate of 3% (n=5).
CONCLUSIONS: Patients admitted to the hospital due to snakebite should be monitored for at least 12 hours, even if there is no sign of clinical envenomation. Antivenom treatment should be administered to the patients requiring clinical staging. Patients should be kept under close monitoring to prevent the development of serious complications such as cellulitis, pulmonary edema, compartment syndrome, and disseminated intravascular coagulation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26221904

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  8 in total

1.  Management and Prognosis of Snake Envenomation Among Pediatric Patients: A National Database Study.

Authors:  Lin-Chi Chiang; Chung-Hsien Chaou; Yi-Yun Li; Chen-June Seak; Shiuan-Ruey Yu; Chih-Chuan Lin
Journal:  J Acute Med       Date:  2022-03-01

2.  Evaluation of Risk Factors and Follow-Up Criteria for Severity of Snakebite in Children.

Authors:  Fesih Aktar; Safak Aktar; Ilyas Yolbas; Recep Tekin
Journal:  Iran J Pediatr       Date:  2016-07-10       Impact factor: 0.364

3.  A Retrospective Study of Acute Renal Failure in Children: Its Incidence, Etiology, Complications and Prognosis.

Authors:  Kadar Ismail Hassan; Jama Hodan M; Chunfu Li
Journal:  Cureus       Date:  2017-05-25

4.  Preclinical Assessment of a New Polyvalent Antivenom (Inoserp Europe) against Several Species of the Subfamily Viperinae.

Authors:  Alejandro García-Arredondo; Michel Martínez; Arlene Calderón; Asunción Saldívar; Raúl Soria
Journal:  Toxins (Basel)       Date:  2019-03-05       Impact factor: 4.546

Review 5.  Practical Review of the Management of Animal Bites.

Authors:  Andrei N Savu; Anna R Schoenbrunner; Rachel Politi; Jeffrey E Janis
Journal:  Plast Reconstr Surg Glob Open       Date:  2021-09-09

6.  Snakebites in Pediatric Patients in Kahramanmaraş: Is Pro-brain Natriuretic Peptide a Prognostic Biomarker for Snakebites?

Authors:  Sevcan İpek; Sukru Gungor; Ufuk U Güllü; Tahir Dalkıran; Mehmet Mercan; Şeyma Demiray; Yunus Gürbüz
Journal:  Cureus       Date:  2022-01-24

7.  When It Comes to Snakebites, Kids Are Little Adults: a Comparison of Adults and Children with Rattlesnake Bites.

Authors:  Michael Levine; Anne-Michelle Ruha; Brian Wolk; Martin Caravati; Jeffrey Brent; Sharan Campleman; Paul Wax
Journal:  J Med Toxicol       Date:  2020-05-11

8.  Acute Exposure to European Viper Bite in Children: Advocating for a Pediatric Approach.

Authors:  Marco Marano; Mara Pisani; Giorgio Zampini; Giuseppe Pontrelli; Marco Roversi
Journal:  Toxins (Basel)       Date:  2021-05-02       Impact factor: 4.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.